Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29203790 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL29203732 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL17339044 | 1.00 | KMT2A (0.45) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL570371 | 0.93 | KMT2A (0.49) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL14717015 | 0.87 | PPARG (0.46) | KMT2AFABP5FABP7TLR2PPARG | |
| SCHEMBL18528956 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL2316716 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL16011495 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL989369 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 | |
| SCHEMBL15878722 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111237-B1 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2015-03-18 | — | — | EP | claimed |
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK AS (DK) | 2026-05-14 | — | — | US | disclosed |
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2026-05-07 | — | — | US | disclosed |
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VITALIXIR (BEIJING) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4633680-A1 | THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4633688-A1 | CELL-BINDING MOTIFS (CBMS) FUNCTIONALIZED POLYMERS | Universiteit Gent (BE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312496-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-10-09 | — | — | US | disclosed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | disclosed |
| EP-4612167-A1 | CNP COMPOUNDS | Novo Nordisk A/S (DK) | 2025-09-10 | — | — | EP | disclosed |
| EP-1054893-A1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | Boston Probes, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6110676-A | PREVENTION OF HYBRIDIZATION OF OLIGONUCLEOTIDES TO RANDOM NUCLEOTIDE SEQUENCES; INCUBATION OF SAMPLE WITH OLIGONUCLEOTIDES, SCREENING FOR HYBRIDIZATION PRODUCTS AND QUANTIFYING | BOSTON PROBES, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-1027372-A1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | Boston Probes, Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-1025120-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | Boston Probes, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999055916-A1 | METHODS, KITS AND COMPOSITIONS FOR DETECTING AND QUANTITATING TARGET SEQUENCES | BOSTON PROBES, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| EP-0946750-A1 | METHODS, KITS AND COMPOSITIONS FOR SUPPRESSING THE BINDING OF DETECTABLE PROBES TO NON-TARGET SEQUENCES IN HYBRIDIZATION ASSAYS | Boston Probes, Inc. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999037670-A1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | BOSTON PROBES, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999022018-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999021881-A1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998024933-A1 | METHODS, KITS AND COMPOSITIONS FOR SUPPRESSING THE BINDING OF DETECTABLE PROBES TO NON-TARGET SEQUENCES IN HYBRIDIZATION ASSAYS | BOSTON PROBES, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612441-B2 | Polypeptide and therapeutic uses thereof | VIP, GCG, GLS | KMT2A 4232/4885FABP5 2385/4885FABP7 977/4885 |
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GCGR, GIPR | KMT2A 2360/4885FABP5 1076/4885FABP7 295/4885 |
| US-20250312496-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, LAP3 | KMT2A 948/4885FABP5 178/4885FABP7 219/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | KMT2A 3978/4885FABP5 2906/4885FABP7 1835/4885 |
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | GLP1R, GIPR, ARRB1 | KMT2A 2440/4885FABP5 2016/4885FABP7 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.